CMAB-020

N/A

Report date: 2024/04/29 17:39:35

Base Information

Drug NameCMAB-020

Drug Alias NameACE-MAB™ proteinCMAB-020STI-4920

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsAngiotensin-converting enzyme 2 modulators

TargetsCoronavirus spike glycoproteinAngiotensin-converting enzyme 2

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLivzon Mabpharm Inc

China Registration ClassN/A

Develop Information

Active CompaniesLivzon Mabpharm Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A